Bristol-Myers Squibb, BioMotiv launch company focused on inflammatory diseases

Bristol-Myers Squibb and BioMotiv have teamed up to create Anteros Pharmaceuticals, a company that will focus on developing a new class of drugs for fibrotic and other inflammatory diseases, the companies said Feb. 4. 

BioMotiv, a company focused on turning breakthrough discoveries from research institutions into drugs, will work  with Yale University and will be solely responsible for research and development for Anteros. 

Bristol-Myers will contribute the IP, data and reagents for Anteros. 

Anteros is the first of several companies Biomotiv and Bristol-Myers plan to form.

Read the full news release here

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars